vertex pharmaceuticals vrtx

Vertex Pharmaceuticals Shares Gain

Vertex Pharmaceuticals (VRTX) Set for Painless Gains After FDA Approval

Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare

Hosted on MSN · 1d

Vertex Pharmaceuticals Just Won a Huge FDA Approval. Is the Biotech Stock a No-Brainer Buy?

Vertex Pharmaceuticals (NASDAQ: VRTX) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 days. On Dec. 20, 2024, the FDA gave a thumbs-up to Alyftrek in treating cystic fibrosis (CF).

The Wall Street Journal on MSN · 3d

Vertex Pharmaceuticals Shares Gain After FDA Approves Non-Opioid Pain Drug

Shares of Vertex Pharmaceuticals rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug Administration approval.

Zacks.com on MSN6h

Vertex (VRTX) Surges 5.3%: Is This an Indication of Further Gains?

Vertex (VRTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...

1VRTX : Vertex Pharmaceuticals Unusual Options Activity

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

What's Happening With VRTX Stock?

With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...

7hon MSN

Vertex stock price target raised to $550 at H.C. Wainwright

H.C. Wainwright analyst Andrew Fein increased the price target for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to $550 from the previous $535, while maintaining a Buy rating on the stock.

14h

HC Wainwright Forecasts Strong Price Appreciation for Vertex Pharmaceuticals (NASDAQ:VRTX) Stock

Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its target price lifted by HC Wainwright from $535.00 to $550.00 in a research report sent to investors on Friday,Benzinga reports. HC Wainwright ...

Vertex wins reimbursement deal for CRISPR-partnered sickle cell therapy in England

Vertex Pharmaceuticals (VRTX) stock gains as England opts to reimburse its CRSPR (CRSP)-partnered gene therapy Casgevy to ...

13h

Vertex Pharmaceuticals: Strong Buy Rating Driven by Journavx Approval and Market Expansion Opportunities

Analyst Salveen Richter of Goldman Sachs maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), reducing the price target ...

Vertex Pharmaceuticals’ (VRTX) “Hold” Rating Reiterated at Needham & Company LLC

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “hold” rating reaffirmed by Needham & Company LLC in a report released on Friday,Benzinga reports. A number of other research ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results